3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
9
Phase 1/2
8
Phase 1
8
Phase 3
1
Phase 2/3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
26
Melanoma
24
Carcinoma, Renal Cell
15
Stomach Neoplasms
9
Lung Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
6
Kidney Neoplasms
5
Carcinoma, Hepatocellular
5
Brain Neoplasms
5
Urinary Bladder Neoplasms
4
Mesothelioma
4
Adenocarcinoma Of Esophagus
4
Skin Neoplasms
3
Neoplasms
3
Neoplasm Metastasis
3
Head and Neck Neoplasms
3
Anus Neoplasms
3
Various Advanced Cancer
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Mesothelioma, Malignant
2
Liver Neoplasms
2
Hodgkin Disease
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Carcinoma
2
Anal Canal Carcinoma
2
Adenocarcinoma
2
von Hippel-Lindau Disease
1
Uveal Melanoma
1
Interventions
Dexamethasone
28
Rituximab
16
pomalidomide
13
Gemcitabine
12
Lenalidomide
11
Cisplatin
11
Bortezomib
11
Paclitaxel
10
Cyclophosphamide
8
Carboplatin
8
carfilzomib
7
selinexor
5
daratumumab
5
Drug Therapy
5
Doxorubicin
5
Cytarabine
5
ibrutinib
4
Vincristine
4
Temozolomide
4
Prednisone
4
Docetaxel
4
Calcium Dobesilate
4
Bevacizumab
4
Aspirin
4
tisagenlecleucel
3
Cetuximab
3
Bendamustine Hydrochloride
3
venetoclax
2
ofatumumab
2
galiximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Recurrence
×
Nivolumab
×
Clear all
NCT03138512
2024-12-18
CheckMate 914
Bristol-Myers Squibb
Phase 3
Completed
1,641 enrolled
21 charts